BetterLife Announces Debt Settlements

VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian securities laws. The Company’s officers and directors settled $1.03 million in amounts owed for a total of 10,308,039 common shares.